Abstract 1534TiP
Background
Metastatic pancreatic ductal adenocarcinoma (mPDAC) patients have very poor prognosis suggesting the urgent need of novel treatments. Repurposing non-oncology already-approved drugs might be an attractive strategy to offer more effective treatment easily tested in clinical trials. Accumulating evidences suggest that epigenetic deregulation is a hallmark of cancer contributing to treatment resistance in several solid tumors, including PDAC. Histone deacetylase inhibitors (HDACi) are epigenetic drugs we have investigated preclinically and clinically as anticancer agents. Valproic acid (VPA) is a generic low-cost anticonvulsant and mood stabilizer, with HDAC inhibitory activity and anticancer properties also demonstrated in PDAC models. Statins use was reported to be associated with lower mortality risk in patients with PDAC and statins have been shown to have a direct antitumor effect when used alone or in combination therapy. We recently demonstrated the capability of VPA/SIM combination to potentiate the antitumor activity of gemcitabine/nab-paclitaxel in vitro and in vivo PDAC preclinical models.
Trial design
VESPA is a patient-centric open-label randomized multicenter phase-II investigator-initiated trial, evaluating the feasibility, safety and efficacy of VPA/SIM plus first-line gemcitabine/nab-paclitaxel-based regimens (AG or PAXG) (experimental arm) vs chemotherapy alone (standard arm) in mPDAC patients. The study involves Italian and Spanish centers and includes an initial 6-patients safety run-in-phase in the experimental arm. A sample size of 240 patients (120 each arm) was calculated under the hypothesis that the addition of VPA/SIM to gemcitabine and nab-paclitaxel-based regimens may extend progression free survival from 6 months in the standard arm to 9 months in the experimental arm. Secondary endpoints are overall survival, response rate, disease control rate, duration of response, CA19.9 reduction, toxicity, and quality of life. The study includes a patient engagement plan and complementary biomarkers studies on tumor and blood samples. Trial recruitment commenced in June 2023 with 50 patients enrolled up to now.
Clinical trial identification
EudraCT 2022-004154-63; NCT05821556.
Editorial acknowledgement
Legal entity responsible for the study
Istituto Nazionale Tumori IRCCS G. Pascale.
Funding
REMEDi4ALL consortium, which has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101057442; and by the Italian Ministry Health- grant RF-2021-12371995.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1525P - Nab-paclitaxel/gemcitabine with or without epigenetic targeting followed by consolidating immune targeting with durvalumab and lenalidomide in patients with advanced pancreatic ductal adenocarcinoma: Results from the SEPION/AIO-PAK-0118 phase I/II study
Presenter: Jens Siveke
Session: Poster session 18
1527P - GnP vs mFOLFIRINOX or S-IROX in metastatic pancreatic cancer: 1-year follow-up updated data from the GENERATE (JCOG1611)
Presenter: Satoshi Kobayashi
Session: Poster session 18
1528P - TCOG T5221 trial: A phase II randomized study of gemcitabine and nab-paclitaxel in combination with S- 1/LV (GASL) or oxaliplatin (GAP) as first-line treatment for metastatic pancreatic cancer
Presenter: Yung-yeh Su
Session: Poster session 18
1531TiP - TWINPEAK phase I/II study, PT886 a bispecific antibody targeting claudin 18.2 and CD47 in combination with chemotherapy and/or pembrolizumab in gastric/GEJ-carcinomas or PDAC
Presenter: Michael Overman
Session: Poster session 18
1532TiP - Zolbetuximab with gemcitabine + nab-paclitaxel (GN) in first-line treatment of Claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase II, open-label, randomized study
Presenter: Wungki Park
Session: Poster session 18
1533TiP - A multicenter, open-label phase II study to evaluate the efficacy and safety of pimicotinib (CSF-1R inhibitor) in combination with chemotherapy with or without toripalimab in patients (pts) with advanced pancreatic ductal adenocarcinoma (aPDAC)
Presenter: Xiaofei Zhang
Session: Poster session 18